特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
325610

レーバー遺伝性視神経症 (LHON) (レーバー視神経萎縮) :パイプライン製品の分析

Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline Review, H2 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 119 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
レーバー遺伝性視神経症 (LHON) (レーバー視神経萎縮) :パイプライン製品の分析
出版日: 2020年09月30日
発行: Global Markets Direct
ページ情報: 英文 119 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レーバー遺伝性視神経症 (LHON) は、先天性の視覚障害の一種です。通常は10~20代で発症しますが、幼児期や中年期以降に発症するまれなケースもあります。男性の方が、女性より発症率が高くなっています。症状には、目の痛みや不快感、しびれ、刺すような痛み、視界の曇りなどが含まれます。素因として、年齢や喫煙、アルコール、抗がん剤、化学薬品に関するストレス、一部の抗生物質やシアンなどが挙げられます。

当レポートでは、レーバー遺伝性視神経症 (LHON) (レーバー視神経萎縮) に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向などについて、体系的な情報を提供しています。

目次

イントロダクション

レーバー遺伝性視神経症 (LHON) (レーバー視神経萎縮) の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

パイプライン製品の概要

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

開発中の製品:企業別

研究中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Alkeus Pharmaceuticals, Inc.
  • Biovista Inc.
  • GenSight Biologics S.A.
  • Ixchel Pharma, LLC
  • Khondrion BV
  • Spark Therapeutics, Inc.
  • Stealth BioTherapeutics Inc.

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

休止状態のプロジェクト

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

図表

List of Tables

List of Tables

  • Number of Products under Development for Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline by Alkeus Pharmaceuticals Inc, H2 2020
  • Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline by Antoxis Ltd, H2 2020
  • Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline by Astellas Pharma Inc, H2 2020
  • Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline by Biovista Inc, H2 2020
  • Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Dormant Projects, H2 2020

List of Figures

List of Figures

  • Number of Products under Development for Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Targets, H2 2020
  • Number of Products by Stage and Targets, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
目次
Product Code: GMDHC12582IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Leber's Hereditary Optic Neuropathy - Pipeline Review, H2 2020, provides an overview of the Leber's Hereditary Optic Neuropathy (Ophthalmology) pipeline landscape.

Leber's hereditary optic neuropathy (LHON) is an inherited form of vision loss. This condition usually begins in a person's teens or twenties, rare cases may appear in early childhood or later in adulthood. Males are affected much more often than females. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer treating drugs, stress related chemicals, some antibiotics and cyanogens.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Leber's Hereditary Optic Neuropathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Leber's Hereditary Optic Neuropathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Leber's Hereditary Optic Neuropathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 1, 7, 2 and 2 respectively. Similarly, the Universities portfolio in Phase III and Phase I stages comprises 1 and 1 molecules, respectively.

Leber's Hereditary Optic Neuropathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Leber's Hereditary Optic Neuropathy (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Leber's Hereditary Optic Neuropathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Leber's Hereditary Optic Neuropathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Leber's Hereditary Optic Neuropathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Leber's Hereditary Optic Neuropathy (Ophthalmology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Leber's Hereditary Optic Neuropathy (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Leber's Hereditary Optic Neuropathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Overview
  • Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Therapeutics Development
  • Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Therapeutics Assessment
  • Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Companies Involved in Therapeutics Development
  • Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Drug Profiles
  • Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Dormant Projects
  • Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Product Development Milestones
  • Appendix
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.